MedPath

Robotic Sacrocolpopexy and Sacrocervicopexy - an Observational Study to Confirm the Peri- and Postoperative Safety and Clinical Performance

Recruiting
Conditions
Sacrocolpopexy
Registration Number
NCT07031050
Lead Sponsor
Distalmotion SA
Brief Summary

This study aims to confirm the perioperative and early postoperative safety and clinical performance (efficacy) of the Dexter Robotic System, in patients undergoing robotic-assisted sacrocolpopexy or sacrocervicopexy.

Detailed Description

Not available

Recruitment & Eligibility

Status
RECRUITING
Sex
All
Target Recruitment
50
Inclusion Criteria
  • Aged > 18 years
  • Women with symptomatic stage I or greater pelvic organ prolapse (POP-Q)
  • Patient agrees to perform the 6-week follow-up assessment as per Standard of Care
Exclusion Criteria
  • Any planned non-urogynaecological concomitant procedures
  • History of previous POP surgery, with the exception of transvaginal approaches without mesh implantation
  • Previous surgery and/or radiation for urologic, gastrointestinal or gynecologic cancer
  • History of Crohn's disease
  • Chronic colitis

Study & Design

Study Type
OBSERVATIONAL
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Primary safety outcomeup to 42 days after surgery

Occurrence of Clavien-Dindo grades III-V adverse events

Primary efficacy outcomeIntraoperative

Successful completion of the Dexter-assisted procedure, i.e. free of any conversion to an open or fully laparoscopic surgical approach

Secondary Outcome Measures
NameTimeMethod

Trial Locations

Locations (6)

Charité - Universitätsmedizin Berlin

🇩🇪

Berlin, Germany

Universitätsklinikum Bonn

🇩🇪

Bonn, Germany

Krankenhaus St. Elisabeth

🇩🇪

Damme, Germany

Universitätsmedizin Essen

🇩🇪

Essen, Germany

Inselspital Bern

🇨🇭

Bern, Switzerland

Spitäler FMI AG

🇨🇭

Interlaken, Switzerland

Charité - Universitätsmedizin Berlin
🇩🇪Berlin, Germany
Jörg Neymeyer, MD
Contact
+4930450515272
joerg.neymeyer@charite.de

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.